Bronchiolitis Obliterans Syndrome Pipeline Insight

DelveInsight’s, “Bronchiolitis Obliterans Syndrome Pipeline Insights, 2023,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Bronchiolitis Obliterans Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Bronchiolitis Obliterans Syndrome Understanding

Bronchiolitis Obliterans Syndrome: Overview

Bronchiolitis obliterans syndrome (BOS) is a form of chronic lung allograft dysfunction that affects the majority of lung transplant recipients. It is the principal factor limiting long-term transplant survival. BOS is characterized by progressive airflow obstruction unexplained by acute rejection, infection, or other coexistent condition. Although BOS is a proven useful clinical syndrome that identifies patients at increased risk for death, its clinical course and underlying causative factors are now recognized to be increasingly heterogeneous. Signs and symptoms of Bronchiolitis Obliterans generally develop approximately 2–8 weeks after exposure to toxic fumes or a respiratory illness. Early after the onset of BOS, a person may have no symptoms as he or she still has very good lung function. This is why it is so important to keep a close follow-up with the transplant team and get frequent lung function monitoring after the transplant. Transplant recipients become symptomatic from BOS because of decreased lung function. Symptoms generally progress slowly over weeks to months. Common symptoms include: Shortness of breath and/or wheezing, Decreased exercise or activity tolerance and endurance, Fatigue and Dry Cough. Bronchiolitis obliterans may result from lung injury caused by a variety of different chemicals and respiratory infections. Inhaled chemicals known to irritate the lungs and lead to the condition include chlorine; ammonia; oxides of nitrogen or sulfur dioxide; welding fumes; or food flavoring fumes (such as diacetyl). Respiratory infections caused by a respiratory syncytial virus, adenovirus, or Mycoplasma pneumonia have been linked with the condition. Bronchiolitis Obliterans Syndrome (BOS) remains the major problem which ceases long-term survival after lung transplantation. Treatment and prevention of BOS are quite challenging. Currently, there is no approved or standard treatment for BOS and successful treatment is defined as stabilization or reduction in the rate of FEV1 decline. An important focus of treatment of BOS patients is optimizing immunosuppression to prevent further lung allograft rejection. Current treatment consists primarily of augmenting immunosuppression by changing medications within therapeutic classes, by adding medications, or by applying non-medicinal immuno-modulating therapies. An increasing number of induction and maintenance immunosuppressive agents have become available over time for use in various combinations allowing for more choice and personalization of immunosuppressive therapy. Despite several advancements, there are pros and cons to each immunosuppressive agent and a regimen that leads to prolonged survival yet is void of associated morbidity including infection, malignancy, and drug-related toxicities, etc. are still under regress research and development.

"Bronchiolitis Obliterans Syndrome Pipeline Insight, 2023" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bronchiolitis Obliterans Syndrome pipeline landscape is provided which includes the disease overview and Bronchiolitis Obliterans Syndrome treatment guidelines. The assessment part of the report embraces, in depth Bronchiolitis Obliterans Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Bronchiolitis Obliterans Syndrome Pipeline Report Highlights

• The Bronchiolitis Obliterans Syndrome companies and academics are working to assess challenges and seek opportunities that could influence in Bronchiolitis Obliterans Syndrome R&D. The Bronchiolitis Obliterans Syndrome therapies under development are focused on novel approaches to treat in Bronchiolitis Obliterans Syndrome.
• This segment of the Bronchiolitis Obliterans Syndrome pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bronchiolitis Obliterans Syndrome Emerging Drugs

Liposomal Cyclosporine A: Zambon

Liposomal Cyclosporine A for Inhalation (LCsAi) is a novel liposomal formulation of cyclosporine A developed for inhaled delivery to the lungs. Calcineurin inhibitors (CNIs), like cyclosporine A, are highly potent immunosuppressive drugs and a cornerstone of lung transplant medicine. LCsAi is administered via a drug-specific Investigational eFlow Technology nebulizer system (PARI Pharma GmbH). The investigational drug-device combination is designed to deliver LCsAi to the site of disease in the lung. LCsAi has received orphan drug designation for the treatment of BOS from the US Food and Drug Administration and European Medicines Agency. Currently the drug, is being investigated in Phase III stage of Clinical trial evaluation for the treatment of Bronchiolitis Obliterans.

Pirfenidone: Genentech

Genentech is developing Pirfenidone, a pyridone small molecule, orally active, an antifibrotic agent that inhibits the synthesis of TGF-beta, a chemical mediator that controls many cell functions, including proliferation and differentiation, and plays a key role in fibrosis. Pirfenidone also inhibits the synthesis of TNF-alpha, a cytokine that is known to have an active role in inflammation. Pirfenidone is in Phase II stage of development for the treatment of Chronic Lung Allograft Dysfunction by Genentech and the University of Michigan in United States. A Phase I trial is also undergoing for Pirfenidone to treat patients with Bronchiolitis Obliterans Syndrome (BOS) associated with lung GVHD after hematopoietic cell transplant (HCT) by the Company and Stanford University in US.

Further product details are provided in the report……..

Bronchiolitis Obliterans Syndrome Therapeutic Assessment

This segment of the Bronchiolitis Obliterans Syndrome pipeline report provides insights about the different Bronchiolitis Obliterans Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Bronchiolitis Obliterans Syndrome Companies

There are approx. 5+ key companies which are developing the therapies for Bronchiolitis Obliterans Syndrome. The companies which have their Bronchiolitis Obliterans Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Zambon.

Phases

DelveInsight’s report covers around 5+ Bronchiolitis Obliterans Syndrome products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Bronchiolitis Obliterans Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Bronchiolitis Obliterans Syndrome Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Bronchiolitis Obliterans Syndrome Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Bronchiolitis Obliterans Syndrome Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bronchiolitis Obliterans Syndrome Pipeline Development Activities

The Bronchiolitis Obliterans Syndrome pipeline report provides insights into different therapeutic candidates in phase III, II, I and preclinical stage. It also analyses Bronchiolitis Obliterans Syndrome therapeutic drugs key players involved in developing key drugs.

Bronchiolitis Obliterans Syndrome Pipeline Development Activities

The Bronchiolitis Obliterans Syndrome pipeline report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bronchiolitis Obliterans Syndrome drugs.

Bronchiolitis Obliterans Syndrome Pipeline Report Highlights

• The Bronchiolitis Obliterans Syndrome companies and academics are working to assess challenges and seek opportunities that could influence Bronchiolitis Obliterans Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Bronchiolitis Obliterans Syndrome.
• In January 2020, Altavant Sciences acquired Onspira Therapeutics. The Company is intended to develop OSP-101 for the treatment of Bronchiolitis Obliterans Syndrome, the leading cause of morbidity and mortality in post-lung transplant patients.
• In May 2017, PARI Pharma gained Orphan Drug Designation for L CsA i for the treatment of BOS by the European Commission. L-CsA-i has also received Orphan Drug Designation from the FDA for the treatment of bronchiolitis obliterans.
• Breath Therapeutics’ drug device platform consists of liposomal drug-aerosol formulations and cutting-edge inhalation technology. The basis for successful inhalation therapy is precise and fast drug delivery into the small airway of the lungs. This requires a uniquely designed drug formulation paired with a high-performance, drug-specific nebulizer.
• In August 2014, Roche and InterMune reach a definitive merger agreement in which Roche acquired InterMune for USD 74.00 per share. This corresponds to a total transaction value of US$ 8.3 billion on a fully diluted basis. This offer represents a premium of 38% to InterMune’s closing price on 22 August 2014 and a premium of 63% to InterMune’s unaffected closing price on 12 August 2014. The merger agreement has been approved by the boards of InterMune and Roche.
• In October 2017, Mereo BioPharma acquired an exclusive license for MPH-966 from AstraZeneca together with an option to acquire the IP based on certain milestones.

Bronchiolitis Obliterans Syndrome Report Insights

• Bronchiolitis Obliterans Syndrome Pipeline Analysis
• Bronchiolitis Obliterans Syndrome wTherapeutic Assessment
• Bronchiolitis Obliterans Syndrome Unmet Needs
• Impact of Bronchiolitis Obliterans Syndrome Drugs

Bronchiolitis Obliterans Syndrome Report Assessment

• Bronchiolitis Obliterans Syndrome Pipeline Product Profiles
• Bronchiolitis Obliterans Syndrome Therapeutic Assessment
• Bronchiolitis Obliterans Syndrome Pipeline Assessment
• Inactive Bronchiolitis Obliterans Syndrome drugs assessment
• Bronchiolitis Obliterans Syndrome Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Bronchiolitis Obliterans Syndrome drugs?
• How many Bronchiolitis Obliterans Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bronchiolitis Obliterans Syndrome?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bronchiolitis Obliterans Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing Bronchiolitis Obliterans Syndrome therapies?
• What are the clinical studies going on for Bronchiolitis Obliterans Syndrome and their status?
• What are the key designations that have been granted to the emerging Bronchiolitis Obliterans Syndrome drugs?